Analyst
Morgan Stanley
Equibles does not estimate personal net worth.
Judith Frommer is recorded as Analyst at Morgan Stanley. Judith Frommer has spoken on 3 earnings calls across 3 companies, most recently for Genmab A/S on August 6, 2026. Those appearances were for Genmab A/S (GMAB), Kymera Therapeutics, Inc. (KYMR) and COMPASS Pathways plc (CMPS). The companies whose calls Judith Frommer spoke on are classified in the Healthcare sector.
“Maybe just a follow-up on PETO in Frontline. Can you help us with thoughts on the nature of the update in Q4?”
“Just on IRF5, I think we're clear on how you think about STAT6 degradation versus inhibition, you know, kind of same question for IRF5. I think we'll get a little bit of preclinical data from an inhibitor next month, and then just on the targeted nature of your degrader, any risk of kind of pan-IRF inhibition?”
“I'm just curious if any of the interactions with FDA included conversation around submissions for the Commissioner's Priority Review application. I think you had said at some point you did have interactions with the agency on that submission?”
Morgan Stanley
Analyst
Transcript header (unverified)
GMAB
Biotechnology · Healthcare
CMPS
Medical Care Facilities · Healthcare
